Alexander J Kula1,2, David K Prince3, Joseph T Flynn4,2, Nisha Bansal3. 1. Division of Nephrology, Seattle Children's Hospital, Seattle, Washington alexander.kula@seattlechildrens.org. 2. Department of Pediatrics, University of Washington, Seattle, Washington. 3. Division of Nephrology, Kidney Research Institute, University of Washington, Seattle, Washington. 4. Division of Nephrology, Seattle Children's Hospital, Seattle, Washington.
Abstract
BACKGROUND: BP is an important modifiable risk factor for cardiovascular events and CKD progression in middle-aged or older adults with CKD. However, studies describing the relationship between BP with outcomes in young adults with CKD are limited. METHODS: In an observational study, we focused on 317 young adults (aged 21-40 years) with mild to moderate CKD enrolled in the Chronic Renal Insufficiency Cohort (CRIC) Study. Exposures included baseline systolic BP evaluated continuously (per 10 mm Hg increase) and in categories (<120, 120-129, and ≥130 mm Hg). Primary outcomes included cardiovascular events (heart failure, myocardial infarction, stroke, or all-cause death) and CKD progression (50% decline of eGFR or ESKD). We used Cox proportional hazard models to test associations between baseline systolic BP with cardiovascular events and CKD progression. RESULTS: Cardiovascular events occurred in 52 participants and 161 had CKD progression during median follow-up times of 11.3 years and 4.1 years, respectively. Among those with baseline systolic BP ≥130 mm Hg, 3%/yr developed heart failure, 20%/yr had CKD progression, and 2%/yr died. In fully adjusted models, baseline systolic BP ≥130 mm Hg (versus systolic BP<120 mm Hg) was significantly associated with cardiovascular events or death (hazard ratio [HR], 2.13; 95% confidence interval [95% CI], 1.05 to 4.32) and CKD progression (HR, 1.68; 95% CI, 1.10 to 2.58). CONCLUSIONS: Among young adults with CKD, higher systolic BP is significantly associated with a greater risk of cardiovascular events and CKD progression. Trials of BP management are needed to test targets and treatment strategies specifically in young adults with CKD.
BACKGROUND: BP is an important modifiable risk factor for cardiovascular events and CKD progression in middle-aged or older adults with CKD. However, studies describing the relationship between BP with outcomes in young adults with CKD are limited. METHODS: In an observational study, we focused on 317 young adults (aged 21-40 years) with mild to moderate CKD enrolled in the Chronic Renal Insufficiency Cohort (CRIC) Study. Exposures included baseline systolic BP evaluated continuously (per 10 mm Hg increase) and in categories (<120, 120-129, and ≥130 mm Hg). Primary outcomes included cardiovascular events (heart failure, myocardial infarction, stroke, or all-cause death) and CKD progression (50% decline of eGFR or ESKD). We used Cox proportional hazard models to test associations between baseline systolic BP with cardiovascular events and CKD progression. RESULTS: Cardiovascular events occurred in 52 participants and 161 had CKD progression during median follow-up times of 11.3 years and 4.1 years, respectively. Among those with baseline systolic BP ≥130 mm Hg, 3%/yr developed heart failure, 20%/yr had CKD progression, and 2%/yr died. In fully adjusted models, baseline systolic BP ≥130 mm Hg (versus systolic BP<120 mm Hg) was significantly associated with cardiovascular events or death (hazard ratio [HR], 2.13; 95% confidence interval [95% CI], 1.05 to 4.32) and CKD progression (HR, 1.68; 95% CI, 1.10 to 2.58). CONCLUSIONS: Among young adults with CKD, higher systolic BP is significantly associated with a greater risk of cardiovascular events and CKD progression. Trials of BP management are needed to test targets and treatment strategies specifically in young adults with CKD.
Authors: Francis B Gabbai; Mahboob Rahman; Bo Hu; Lawrence J Appel; Jeanne Charleston; Gabriel Contreras; Marquetta L Faulkner; Leena Hiremath; Kenneth A Jamerson; Janice P Lea; Michael S Lipkowitz; Velvie A Pogue; Stephen G Rostand; Miroslaw J Smogorzewski; Jackson T Wright; Tom Greene; Jennifer Gassman; Xuelei Wang; Robert A Phillips Journal: Clin J Am Soc Nephrol Date: 2012-08-30 Impact factor: 8.237
Authors: Alfred K Cheung; Tara I Chang; William C Cushman; Susan L Furth; Joachim H Ix; Roberto Pecoits-Filho; Vlado Perkovic; Mark J Sarnak; Sheldon W Tobe; Charles R V Tomson; Michael Cheung; David C Wheeler; Wolfgang C Winkelmayer; Johannes F E Mann Journal: Kidney Int Date: 2019-05 Impact factor: 10.612
Authors: Paul Muntner; Amanda Anderson; Jeanne Charleston; Zhen Chen; Virginia Ford; Gail Makos; Andrew O'Connor; Kalyani Perumal; Mahboob Rahman; Susan Steigerwalt; Valerie Teal; Raymond Townsend; Matthew Weir; Jackson T Wright Journal: Am J Kidney Dis Date: 2009-12-05 Impact factor: 8.860
Authors: Mark Mitsnefes; Joseph Flynn; Silvia Cohn; Joshua Samuels; Tom Blydt-Hansen; Jeffrey Saland; Thomas Kimball; Susan Furth; Bradley Warady Journal: J Am Soc Nephrol Date: 2009-11-16 Impact factor: 10.121
Authors: James P Lash; Alan S Go; Lawrence J Appel; Jiang He; Akinlolu Ojo; Mahboob Rahman; Raymond R Townsend; Dawei Xie; Denise Cifelli; Janet Cohan; Jeffrey C Fink; Michael J Fischer; Crystal Gadegbeku; L Lee Hamm; John W Kusek; J Richard Landis; Andrew Narva; Nancy Robinson; Valerie Teal; Harold I Feldman Journal: Clin J Am Soc Nephrol Date: 2009-06-18 Impact factor: 8.237
Authors: Katherine T Mills; Jing Chen; Wei Yang; Lawrence J Appel; John W Kusek; Arnold Alper; Patrice Delafontaine; Martin G Keane; Emile Mohler; Akinlolu Ojo; Mahboob Rahman; Ana C Ricardo; Elsayed Z Soliman; Susan Steigerwalt; Raymond Townsend; Jiang He Journal: JAMA Date: 2016 May 24-31 Impact factor: 56.272
Authors: Chike C Nwabuo; Duke Appiah; Henrique T Moreira; Henrique D Vasconcellos; Yuichiro Yano; Jared P Reis; Ravi V Shah; Venkatesh L Murthy; Norrina B Allen; Stephen Sidney; Paul Muntner; Cora E Lewis; Donald M Lloyd-Jones; Pamela J Schreiner; Samuel S Gidding; João A C Lima Journal: Eur J Prev Cardiol Date: 2021-10-25 Impact factor: 7.804
Authors: Norrina B Allen; Juned Siddique; John T Wilkins; Christina Shay; Cora E Lewis; David C Goff; David R Jacobs; Kiang Liu; Donald Lloyd-Jones Journal: JAMA Date: 2014-02-05 Impact factor: 157.335